Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses.

Scand J Immunol. 1996 Feb;43(2):181-92. Unique Identifier : AIDSLINE MED/96228950
Gueirard P; Minoprio P; Guiso N; Laboratoire des Bordetella, Institut Pasteur, Paris, France.

Abstract: Humoral and cellular immune responses were analysed in mice inoculated intranasally with Bordetella bronchiseptica. After infection, the number of bacteria that colonized the respiratory tract of the mice increased during the first day and decreased thereafter. Total IgG levels increased as early as 14 days after infection and decreased with time after infection, whereas total IgA and IgM levels were lower but remained stable. Specific antibodies to the bacteria were mainly IgG2a and IgA and persisted up to 10 months after infection. Some of these specific antibodies were directed against adenylate cyclase-haemolysin, the bacterial factor that had been shown to be necessary for initiation of infection. The proliferation of Bordetella bronchiseptica-reactive spleen cells occurred during the acute phase of infection. T cells from infected mice produced increasing amounts of IFN gamma and IL-2 after infection. Although very low levels of IL-10 were produced, no IL-4 was detected after bacterial stimulation in vitro. These results suggest that Bordetella bronchiseptica infection induces primarily a Th1-type T-cell response. Importantly, the authors demonstrated that antibody and T-cell responses directed against bacterial determinants of the virulent strain and to purified adenylate cyclase-haemolysin were long-lasting. This observation could be due to the fact that Bordetella bronchiseptica may persist intracellularly in the host as it was demonstrated in vitro.

Keywords: Administration, Intranasal Animal Antibodies, Bacterial/*BIOSYNTHESIS Antigens, Bacterial/IMMUNOLOGY Bacterial Proteins/IMMUNOLOGY Bacterial Toxins/IMMUNOLOGY Bordetella bronchiseptica/GROWTH & DEVELOPMENT/*IMMUNOLOGY Female IgA/BIOSYNTHESIS IgG/BIOSYNTHESIS Immune Tolerance Immunity, Cellular Immunization Lung/MICROBIOLOGY Mice Mice, Inbred BALB C Mitogens/PHARMACOLOGY Protein Precursors/IMMUNOLOGY Spleen/IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocytes/*IMMUNOLOGY Th1 Cells/IMMUNOLOGY JOURNAL ARTICLE
960930
M9690880

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .